Mipsagargin

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameMipsagargin
Drug Alias Name米沙伽近mipsagargina美沙格净mipsagarginummipsagargine +[9] 
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionSarcoplasmic/endoplasmic reticulum calcium ATPase 2 inhibitorsSarcoplasmic/endoplasmic reticulum calcium ATPase 1 inhibitors
TargetsSarcoplasmic/endoplasmic reticulum calcium ATPase 2Sarcoplasmic/endoplasmic reticulum calcium ATPase 1
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Renal Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesInspyr Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenspera Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Renal Cell +[5] 

Other Information

ATC CodeN/A
Related LinksKEGG